Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
53 studies found for:    "ZAP70-related severe combined immunodeficiency" OR "Severe Combined Immunodeficiency"
Show Display Options
Rank Status Study
21 Completed Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency
Condition: Severe Combined Immunodeficiency Syndrome
Intervention: Drug: CD34+ cells transduced with ADA retrovir
22 Completed Gene Therapy for ADA-SCID
Condition: Severe Combined Immunodeficiency Syndrome
Intervention: Genetic: gene transduced PBL and/or gene transduced HSC
23 Withdrawn Sirolimus Prophylaxis for aGVHD in TME SCID
Conditions: Severe Combined Immunodeficiency;   Transplacental Maternal Engraftment;   Stem Cell Transplant
Intervention: Drug: Sirolimus
24 Active, not recruiting Autologous Transplant of EFS-ADA Modified Bone Marrow Cells for ADA-Deficient Severe Combined Immunodeficiency (SCID)
Condition: ADA-SCID
Intervention: Genetic: EFS-ADA transduced CD34+ cells from the bone marrow
25 Terminated
Has Results
Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders
Conditions: Severe Combined Immunodeficiency Disease;   Severe Primary Immunodeficiency Disorder;   Undefined T Cell Deficiency Disorder;   Wiskott-Aldrick Syndrome
Interventions: Biological: Campath -1H;   Drug: Fludarabine;   Biological: Anti-CD45;   Procedure: Stem cell infusion
26 Completed IMM 0212: Busulfan With Fludarabine and Antithymocyte Globulin as Preparative Therapy for Hematopoietic Stem Cell Transplant for the Treatment of Severe Congenital T-Cell Immunodeficiency
Conditions: T-Cell Immune Deficiency Diseases;   Severe Combined Immunodeficiency
Intervention: Drug: Busulfan, Fludarabine and ATG
27 Recruiting Lentiviral Gene Therapy for Adenosine Deaminase (ADA) Deficiency
Conditions: Adenosine Deaminase Deficiency;   Severe Combined Immunodeficiencies (SCID)
Intervention: Genetic: EF1αS-ADA lentiviral vector transduced patient Cd34+ cells
28 Recruiting EZN-2279 in Patients With ADA-SCID
Conditions: ADA-SCID;   Adenosine Deaminase Deficiency;   Severe Combined Immunodeficiency
Interventions: Biological: EZN-2279;   Biological: Adagen
29 Recruiting Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders
Conditions: Lymphohistiocytosis, Hemophagocytic;   Common Variable Immunodeficiency;   Severe Combined Immunodeficiency
Intervention:
30 Enrolling by invitation Genetic Analysis of Immune Disorders
Conditions: Healthy;   Immunologic Deficiency Syndrome;   Job's Syndrome;   Severe Combined Immunodeficiency
Intervention:
31 Recruiting Patients Treated for SCID (1968-2010)
Conditions: SCID;   ADA-SCID;   XSCID;   Leaky SCID;   Omenn Syndrome;   Reticular Dysgenesis
Intervention:
32 Recruiting Natural History Study of SCID Disorders
Conditions: SCID;   Leaky SCID;   Omenn Syndrome;   Reticular Dysgenesis;   ADA Deficiency;   XSCID
Intervention:
33 Unknown  Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases
Conditions: Bone Marrow Failure;   Osteopetrosis;   Fanconi Anemia;   Severe Combined Immunodeficiency
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Cyclophosphamide 40;   Drug: Cyclophosphamide 30
34 Withdrawn Quality of Life and Neuropsychiatric Sequelae in Patients Treated With Gene Therapy for ADA-SCID and in Their Parents
Condition: ADA-SCID
Intervention:
35 Recruiting Participation in a Research Registry for Immune Disorders
Conditions: ADA-SCID;   Adenosine Deaminase Deficiency;   Wiskott- Aldrich Syndrome;   Primary Immunodeficiencies;   Severe Combined Immune Deficiency
Intervention:
36 Recruiting Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products
Conditions: Severe Combined Immunodeficiency;   Malignancy, Hematologic;   Neuroblastoma;   Neoplasm;   Mucopolysaccharidosis I
Intervention: Procedure: Venipuncture
37 Completed Gene Therapy ADA Deficiency
Condition: Adenosine Deaminase Deficiency
Intervention: Biological: Intravenous infusion of transduced cells
38 Completed Treatment of SCID Due to ADA Deficiency With Autologous Transplantation of Cord Blood or Hematopoietic CD 34+ Cells After Addition of a Normal Human ADA cDNA by the EFS-ADA Lentiviral Vector
Conditions: Adenosine Deaminase Deficiency;   ADA-SCID
Intervention: Genetic: Lentiviral Gene Transfer
39 Completed Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients
Conditions: Immunologic Deficiency Syndrome;   Agammaglobulinemia;   Severe Combined Immunodeficiency;   Wiskott-Aldrich Syndrome;   Common Variable Immunodeficiency
Interventions: Drug: Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified;   Drug: Dextrose, 5% in Water
40 Terminated Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies
Conditions: Immunologic Deficiency Syndromes;   Chediak-Higashi Syndrome;   Common Variable Immunodeficiency;   Graft Versus Host Disease;   X-Linked Lymphoproliferative Syndrome;   Familial Erythrophagocytic Lymphohistiocytosis;   Hemophagocytic Lymphohistiocytosis;   X-linked Agammaglobulinemia;   Wiskott-Aldrich Syndrome;   Chronic Granulomatous Disease;   X-linked Hyper IgM Syndrome;   Severe Combined Immunodeficiency;   Leukocyte Adhesion Deficiency Syndrome;   Virus-Associated Hemophagocytic Syndrome
Interventions: Drug: anti-thymocyte globulin;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: etoposide;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: prednisone;   Procedure: Allogeneic Bone Marrow Transplantation

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-53) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.